Search
for
Sort by
Research 421–450 of 579
- Multiple Autoimmune Syndrome type 3- Thyroiditis, Vitiligo and Alopecia Areata
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- Personalized Medicine in the Field of Inflammatory Skin Disorders
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- Irish dermatologists’ experience with JAK inhibitors in alopecia areata
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Jak inhibitors in the treatment of alopecia areata - a literature review
- Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study
- Efficacy and Safety of Tofacitinib in Paediatric Alopecia Aerata - A Prospective Observational Study
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Tofacitinib in alopecia areata and HIV: A curious intersection of immunomodulation, hair regrowth, and hypertrichosis
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Central serous chorioretinopathy after scalp and eyebrow intralesional triamcinolone acetonide injections: Report of two cases
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- 43853 Case of Reactive Keratoacanthomas arising Eight Years After Multicolored Tattoo Placement
- Janus kinase inhibitor as a therapeutic option in alopecia areata. Case report
- Reply to early onset effluvium secondary to COVID-19 and body-hair effluvium
- Mesenchymal-epidermal interactions in hair follicle cycling and regeneration
- Faculty Opinions recommendation of Hair regrowth following a Wnt- and follistatin containing treatment: safety and efficacy in a first-in-man phase 1 clinical trial.
- The JAK/STAT signaling pathway: from bench to clinic